Current Oncology Reports

, 16:366

Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?

Gastrointestinal Cancers (B Czito, Section Editor)

DOI: 10.1007/s11912-013-0366-9

Cite this article as:
Halperin, D.M. & Varadhachary, G.R. Curr Oncol Rep (2014) 16: 366. doi:10.1007/s11912-013-0366-9
Part of the following topical collections:
  1. Topical Collection on Gastrointestinal Cancers

Abstract

Pancreatic adenocarcinoma represents a significant cause of morbidity and mortality in the modern era. Despite advances in the management of unresectable and advanced disease, the only potential avenue for cure at this time is resection. As our radiographic and surgical techniques have improved, we are better able to select patients who are the best candidates for a margin-negative resection, with or without the use of preoperative therapy. There is an emerging consensus on the definition of borderline resectable pancreatic cancer, but much work still needs to be done given the heterogeneous patient population, intervention, and outcome metrics used in previous retrospective and prospective studies. When designing future prospective trials of novel preoperative approaches, standardization of the stage of disease for the study population is essential to allow for accurate interpretation of study results. Ultimately, to make significant progress in localized pancreatic cancer, we urgently need effective novel therapeutic agents used in an optimal sequence with surgery.

Keywords

Pancreatic cancer Borderline Neoadjuvant Pancreatic adenocarcinoma Localized pancreatic cancer Borderline resectable pancreatic cancer Gastrointestinal cancers 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Gastrointestinal Medical Oncology, Unit 426The University of Texas M. D. Anderson Cancer CenterHoustonUSA